Pharmaceutical composition for preventing or treating polycystic ovarian syndrome comprising herbal medicine and metformin as active ingredients

A composition of Siryung-Tang and metformin effectively addresses PCOS by reducing cystic follicles and normalizing hormone levels, providing a dual therapeutic and preventive solution for PCOS.

KR103045041B1Active Publication Date: 2026-11-10DONGGUK UNIV WISE CAMPUS IND -ACAD COOP FOUNDATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020230189798
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-22
Publication Date
2026-11-10
Estimated Expiration
2043-12-22

AI Technical Summary

Technical Problem

Current treatments and diagnostic agents for polycystic ovary syndrome (PCOS) are inadequate, and there is a lack of clinically applicable genetic tests, necessitating the development of effective compositions for prevention, treatment, and improvement of PCOS.

Method used

A pharmaceutical and health functional food composition comprising Siryung-Tang and metformin as active ingredients, which synergistically inhibit nitric oxide production, regulate inflammation-related factors, and modulate hormone levels to improve PCOS symptoms.

Benefits of technology

The combination of Siryung-Tang and metformin significantly reduces cystic follicles, increases graafian follicles, and normalizes hormone levels, offering a comprehensive approach to treating and preventing PCOS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023144592307-PAT00003_ABST
    Figure 112023144592307-PAT00003_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of diseases related to polycystic ovary syndrome, comprising a herbal medicine (Siryung-Tang) and metformin as active ingredients. When Siryung-Tang and metformin are administered in combination rather than individually, the composition exhibits: inhibition of nitric oxide production; regulation of the secretion (expression) of inflammation-related factors; reduction in the number of cystic follicles in the ovaries; increase in the number of graafian follicles; and reduction in blood concentrations of testosterone, estradiol, and luteinizing hormone. By confirming that effects such as an increase in blood follicle-stimulating hormone concentration are more significantly observed, it can be usefully utilized as a composition for the prevention, treatment, or improvement of polycystic ovary syndrome or related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome comprising a herbal medicine (Siryung-Tang) and metformin as active ingredients. Background Technology

[0002] Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder affecting 4 to 12 percent of women of childbearing age. The diagnostic criteria for PCOS presented by the National Institutes of Health (NIH) in 1990 require both chronic anovulation and clinical or biochemical hyperandrogenism. In contrast, the diagnostic criteria of the European / American Association of Reproductive Endocrinologists, revised in 2003, define PCOS as satisfying at least two of three criteria: chronic anovulation, clinical or biochemical hyperandrogenism, and the presence of about 10 small follicles arranged in a bead-like pattern along the margins of enlarged ovaries.

[0003] Symptoms of polycystic ovary syndrome include oligomenorrhea, amenorrhea, hyperandrogenism, hyperandrogenemia, and polycystic ovary morphology. In addition, based on studies regarding age and body weight, approximately 50% of women with polycystic ovary syndrome commonly exhibit biochemical characteristics such as serum luteinizing hormone hypersecretion, insulin resistance, and compensatory hyperinsulinemia compared to the control group.

[0004] As an example of a condition related to Polycystic Ovary Syndrome, premature ovarian failure occurs when ovarian function does not operate normally and is classified into ovulatory cycle irregularity, luteal phase insufficiency, and anovulatory cycle irregularity. Anovulatory cycle irregularity occurs physiologically during puberty and menopause, but it leads to infertility in women of childbearing age. Luteal phase insufficiency causes infertility and miscarriage due to the rapid regression of luteal phase function. Ovulatory cycle irregularity is attributed to abnormalities in the length of the follicular phase, as it involves abnormalities solely in cycle length. While this ovarian failure may typically manifest as menopausal symptoms as a woman ages and reaches the time of menopause, it can also appear abnormally in women under 40, causing difficulties in conception. If symptoms worsen in this state, it can lead to premature menopause.

[0005] The exact cause of polycystic ovary syndrome (PCOS) has not yet been clearly identified. As with other complex diseases, both genetic and environmental factors are believed to play a role in the development of PCOS. With advancements in research techniques, the focus of primary pathophysiology has shifted from the ovaries to the hypothalamic-pituitary axis, and is subsequently trending toward defects in insulin action. While research results regarding the association between various genetic factors and PCOS have been reported, there are currently no clinically applicable genetic tests available. Consequently, efforts are required to develop treatments and diagnostic agents for PCOS. Prior art literature

[0006] 1. Republic of Korea Published Patent KR 10-2021-0045404 (Published April 26, 2021) The problem to be solved

[0007] The object of the present invention is to provide a composition for the prevention, treatment, or improvement of polycystic ovary syndrome. means of solving the problem

[0008] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome or related diseases comprising Siryung-Tang and metformin as active ingredients.

[0009] In addition, the present invention provides a health functional food composition for preventing or improving polycystic ovary syndrome or related diseases, comprising Siryung-Tang and metformin as active ingredients.

[0010] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of ovotoxity comprising Siryung-Tang and metformin as active ingredients.

[0011] In addition, the present invention provides a health functional food composition for preventing or improving ovotoxity comprising Siryung-Tang and metformin as active ingredients. Effects of the invention

[0012] According to the present invention, when Siryung-Tang and metformin are administered in combination rather than individually, effects such as inhibition of nitric oxide production; regulation of secretion (expression) of inflammation-related factors; reduction of the number of cystic follicles in the ovary; increase in the number of graafian follicles; reduction of blood testosterone, estradiol, and luteinizing hormone concentrations; and increase of blood follicle-stimulating hormone concentration are observed more significantly, thereby making it useful as a composition for the prevention, treatment, or improvement of polycystic ovary syndrome or related diseases. Brief explanation of the drawing

[0013] Figure 1 shows the results of analyzing the effects of Siryung-Tang (hereinafter referred to as SRT) and metformin (hereinafter referred to as Met) (hereinafter, the above SRT and Met are referred to as samples) on dystoxicity. ###p<0.001 (vs. normal group) and *p<0.05, ***p<0.001 (vs. VCD alone treatment group). Figure 2 shows the results of analyzing the effect of the samples on nitric oxide (hereinafter referred to as NO) production. ###p<0.001 (vs normal group) and *p<0.05, ***p<0.001 (vs LPS alone treatment group). Figure 3 shows the results of measuring the secretion levels of IL-1β and IL-6 by performing an ELISA analysis to confirm the effect of the samples on the secretion of pro-inflammatory cytokines. ###p<0.001 (vs normal group) and *p<0.05, ***p<0.001 (vs LPS alone treatment group). Figure 4 shows the results of analyzing the effect of the sample on the expression of inflammation-related factors. Figure 5 shows the results of measuring estradiol secretion by performing an ELISA analysis to determine the effect of the samples on steroid hormone production in granulosa cells. ###p<0.001 (vs normal group) and *p<0.05, ***p<0.001 (vs FSH and AD treated groups). Figure 6 shows the results of the analysis of the effects of the samples on the production of cystic follicles and graafian follicles within the ovaries. #p<0.05, ###p<0.001 (vs normal group) and *p<0.05, ***p<0.001 (vs control group). Figure 7 shows the results of the analysis of the effects of the samples on blood concentrations of testosterone, estradiol, luteinizing hormone (hereinafter referred to as LH), and follicle-stimulating hormone (hereinafter referred to as FSH). ##p<0.01, ###p<0.001 (vs normal group) and **p<0.01, ***p<0.001 (vs control group). Figure 8 shows the results of analyzing the effect of the sample on blood AST (aspartate aminotransferase) and ALT (alanine aminotransferase) concentrations. Specific details for implementing the invention

[0014] The present invention will be described in more detail below.

[0016] The present invention provides a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome or related diseases; or ovotoxity, comprising Siryung-Tang and metformin as active ingredients.

[0017] The above Silyeongtang is Bupleurum ( Bupleurum falcatumLinne), Taxa ( Alisma orientale Juzepzuk), Atractylodes ( Atractylodes macrocephala Koidzumi), low spirit ( Polyporus umbellatus Fries), Poria cocos ( Poria cocos Wolf), Banha ( Pinellia ternata Breitenbach), gold ( Scutellaria baicalensis Georgi), ginseng ( Panax ginseng CA Meyer), licorice ( Glycyrrhiza uralensis Fischer), broiler chicken ( Cinnamomum cassia J.Presl) and ginger ( Zingiber officinale It may include, but is not limited to, Roscoe.

[0018] Silyeongtang is a prescription used to treat diarrhea accompanied by fever and dry mouth, as well as malaria characterized by high fever and low cold, resulting in dry mouth, chest tightness, and anxiety. The pharmacological effects of Silyeongtang include anti-inflammatory, steroid-like, and immunosuppressive properties; it has also been reported to be effective in improving lymphedema that occurs after radiation therapy, breast cancer surgery, or hip replacement surgery.

[0019] Metformin is a compound represented by the following chemical formula 1, the IUPAC name of which is 3-(diaminomethylidene)-1,1-dimethylguanidine (3-(diaminomethylidene)-1,1-dimethylguanidine, C4H 11N5) Metformin, which is widely used as an insulin sensitizer and is recognized as a treatment for type 2 diabetes, is used to reduce insulin resistance in women with polycystic ovary syndrome, thereby reducing blood insulin and androgen levels and treating anovulation.

[0020] [Chemical Formula 1]

[0021]

[0022] The diseases associated with the above polycystic ovary syndrome may be one or more selected from the group consisting of hyperandrogenism, amenorrhea, hypomenorrhea, dysfunctional uterine bleeding, premature menopause, infertility, and endometriosis, but are not limited thereto.

[0023] The above-mentioned dystoxicity may be induced by VCD (4-vinylcyclohexene diepoxide).

[0024] The above pharmaceutical composition can inhibit the production of nitric oxide.

[0025] In addition, the above pharmaceutical composition may inhibit the expression of one or more selected from the group consisting of IL-1β (Interleukin-1β), IL-6 (Interleukin-6), iNOS (Inducible nitric oxide synthase), COX-2 (cyclooxygenase-2), and estradiol, but is not limited thereto.

[0026] In addition, the above pharmaceutical composition may decrease the concentration of testosterone, estradiol, or luteinizing hormone in the blood, or increase the concentration of follicle-stimulating hormone in the blood.

[0027] In addition, the above pharmaceutical composition can reduce the number of cystic follicles or increase the number of graafian follicles.

[0028] The pharmaceutical composition of the present invention may be manufactured in a unit dose form or contained in a multi-dose container by formulation using a pharmaceutically acceptable carrier according to a method that can be easily carried out by a person skilled in the art to which the invention belongs.

[0029] The above-mentioned pharmaceutically acceptable carriers are those commonly used in formulations and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

[0030] In the present invention, the content of the additive included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.

[0031] The above pharmaceutical composition may be formulated in the form of one or more external skin preparations selected from the group consisting of injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, tablets, creams, gels, patches, sprays, ointments, warning agents, lotions, liniments, pastes, and cataplasms, but is not limited thereto.

[0032] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable carriers and diluents for formulation. The pharmaceutically acceptable carriers and diluents include, but are not limited to, excipients such as starch, sugars, and mannitol; fillers and extenders such as calcium phosphate; cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose; binders such as gelatin, alginates, and polyvinylpyrrolidone; lubricants such as talc, calcium stearate, hydrogenated castor oil, and polyethylene glycol; disintegrants such as povidone and crospovidone; and surfactants such as polysorbate, cetyl alcohol, and glycerol. The pharmaceutically acceptable carriers and diluents may be biologically and physiologically affinities for the target. Examples of diluents include, but are not limited to, saline solution, aqueous buffer solution, solvent, and / or dispersion media.

[0033] The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method. In the case of oral administration, it may be formulated into tablets, troches, lozenges, water-soluble suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups, elixirs, etc. In the case of parenteral administration, it may be formulated into injectable solutions, suppositories, powders for respiratory inhalation, aerosols for sprays, ointments, powders for topical application, oils, creams, etc.

[0034] The dosage of the pharmaceutical composition of the present invention may vary depending on the patient's condition, weight, age, gender, health status, dietary constitutional specificity, properties of the formulation, degree of disease, time of administration of the composition, method of administration, duration or interval of administration, excretion rate, and form of the drug, and may be appropriately selected by a person skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg / kg, but is not limited thereto, and may be administered once or several times a day.

[0035] The above pharmaceutical composition may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method. The pharmaceutical effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, method of administration, time of administration, route of administration, etc., and a person skilled in the art can easily determine and prescribe a dosage effective for the intended treatment. The pharmaceutical composition of the present invention may be administered once a day or divided into several doses.

[0037] In addition, the present invention provides a health functional food composition for the prevention or improvement of polycystic ovary syndrome or related diseases; or ovotoxity, comprising Siryung-Tang and metformin as active ingredients.

[0038] The present invention can be generally used as a commonly used food.

[0039] The food composition of the present invention may be used as a health functional food. The term “health functional food” refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body in accordance with the Health Functional Foods Act, and the term “functional properties” refers to consuming the food for the purpose of obtaining beneficial effects for health purposes, such as regulating nutrients or physiological actions on the structure and function of the human body.

[0040] The above-mentioned health functional food composition may include ordinary food additives, and unless otherwise specified, suitability as a “food additive” shall be determined in accordance with the specifications and standards for the relevant item, based on the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety.

[0041] Examples of items listed in the above “Food Additives Codex” include chemically synthesized products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid; natural additives such as persimmon dye, licorice extract, crystalline cellulose, sorghum dye, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline noodle additives, preservative preparations, and tar dye preparations.

[0042] The food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. For example, among health functional foods in capsule form, hard capsules can be manufactured by mixing and filling a conventional hard capsule with the composition according to the present invention and additives such as excipients, and soft capsules can be manufactured by mixing the composition according to the present invention with additives such as excipients and filling it into a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as needed.

[0043] The definitions of terms regarding the above excipients, binders, disintegrants, lubricants, flavoring agents, etc., are those described in literature known in the art and include those with identical or similar functions. There are no special restrictions on the types of food mentioned above, and they include all health functional foods in the conventional sense.

[0044] In the present invention, the term “prevention” refers to any act of suppressing or delaying the said disease or symptoms by administering the composition according to the present invention.

[0045] In the present invention, the term “treatment” refers to any act of improving or beneficially altering the said disease or symptoms through the administration of the composition according to the present invention.

[0046] In the present invention, the term “improvement” refers to any act of improving the poor condition of the disease or symptoms through the administration of the composition according to the present invention.

[0048] Hereinafter, the present invention will be described in detail with reference to examples to aid in understanding. However, the following examples are merely illustrative of the content of the present invention and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those with average knowledge in the art.

[0050] [Experimental Example 1] Experimental Preparation

[0051] 1-1. Sample

[0052] The SRT (Siryung-Tang) used as a sample of the present invention was prepared as follows. The constituent medicinal ingredients of Siryung-Tang [Bupleurum ( Bupleurum falcatum Linne), Taxa ( Alisma orientale Juzepzuk), Atractylodes ( Atractylodes macrocephala Koidzumi), low spirit ( Polyporus umbellatus Fries), Poria cocos ( Poria cocos Wolf), Banha ( Pinellia ternata Breitenbach), gold ( Scutellaria baicalensis Georgi), ginseng ( Panax ginseng CA Meyer), licorice ( Glycyrrhiza uralensis Fischer), broiler chicken ( Cinnamomum cassia J.Presl) and health( Zingiber officinale Roscoe) was purchased from Human Hub Co., Ltd., selected, and refined for use.

[0053] Approximately 66g of Silyeongtang (equivalent to 2 doses of Bupleurum chinense, 9.8g Alisma orientale, 5.6g Atractylodes macrocephala, 5.6g Polyporus umbellatus, 5.6g Poria cocos, 5.2g Pinellia ternata, 4.6g Scutellaria baicalensis, 4.6g Panax ginseng, 4.6g Glycyrrhiza glabra, 2.2g Cinnamomum cassia, and 6g dried ginger) was placed in a round-bottom flask with 800ml of distilled water and heated under reflux for 4 hours. The extract was cooled to room temperature and filtered twice using filter paper; the filtered solution was then concentrated under reduced pressure and freeze-dried to obtain 12.7g of water extract (yield 19.3%).

[0054] In addition, the Met (metformin) used as a sample of the present invention was purchased from Sigma-Aldrich (USA).

[0056] 1-2. Cell Model

[0057] The human granulosa cell line COV434 used as the cell model of the present invention was purchased from Sigma-Aldrich (St. Louis, MO, USA), and the mouse macrophage cell line RAW 264.7 was purchased from the Korea Cell Line Bank (KCLB, Seoul, Korea). The above cells were each inoculated into DMEM (Dulbecco's Modified Eagle's Medium, WELGENE) medium containing 10% FBS (fetal bovine serum, WELGENE, Daegu, Korea) and 1% penicillin / streptomycin (penicillin / streptomycin, Thermo Fisher, Grand Island, NY, USA), and cultured in an incubator (Thermo Fisher Scientific, Langenselbold, Germany) at 37°C and 5% CO2. For the COV434 cells, the process of adding L-glutamine (L-glutamine, 2 mM) to the culture medium was added under the above culture conditions.

[0059] 1-3. Animal Models

[0060] A 6-week-old female SD (Sprague-Dawly) rat used as the animal model for the present invention was purchased from Young Bio Co., Ltd. (Seongnam, Korea). The animal model was acclimated to the laboratory environment by providing sufficient food and water for one week before being used in the experiment. The laboratory environment maintained a temperature of 22±2℃ and continued a condition of day and night in 12-hour cycles until the end of the experiment.

[0062] [Experimental Example 2] Statistical Analysis

[0063] The results of cell experiments were expressed as mean ± standard deviation (SD), and the results of animal experiments were expressed as mean ± standard error of the mean (SEM). To test for significance, one-way analysis of variance (ANOVA) was performed using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA), followed by Tukey's multiple comparison test at the p<0.05 level.

[0065] [Example 1] Cytoprotective effect against dystoxicity

[0066] To determine the effect of the samples on oligotoxicity, an MTT assay was performed. COV434 cells were seeded at 1×10⁴ cells / well in a 96-well plate and serum starvation was maintained for 4 hours. Subsequently, the cells were pretreated with SRT (10, 50, or 100 μg / ml) or / and Met (1 mM) for 1 hour, followed by sequential treatment with VCD (4-vinylcyclohexene diepoxide, 0.5 mM, Sigma-Aldrich), and then incubated for 24 hours at 37°C and 5% CO2. Subsequently, 10 μL of MTT solution (2 mg / mL) was added per well and reacted for 2 hours in an incubator at 37°C and 5% CO2. After completely removing the MTT solution and culture medium, the formazan crystals formed within the cells were dissolved with DMSO (dimethyl sulfoxide, 100 μL) and placed in an ELISA plate reader (Tecan Austria GmbH, Gr Absorbance was measured at 540 nm using a dig (Austria) device. Cell viability was expressed as a percentage for the normal group (sample and untreated VCD group).

[0067] As a result, as shown in Figure 1, cell viability was significantly reduced in the control group (VCD-only treatment group) compared to the normal group (sample and VCD-untreated group), and cell viability in the SRT-only treatment group significantly increased compared to the control group starting from a treatment concentration of 50 μg / ml. In addition, among the sample treatment groups, the SRT-Met combination treatment group showed a higher cell viability compared to the SRT-only treatment group (based on the same SRT treatment concentration). From the above results, it was confirmed that SRT-Met combination treatment exhibits a cytoprotective effect against dystoxicity.

[0069] [Example 2] NO Production Analysis

[0070] To determine the effect of the samples on NO (nitric oxide) production, RAW 264.7 cells cultured in serum-free medium for at least 6 hours were pretreated with SRT (10, 100, 300, or 500 μg / ml) or / and Met (1 mM) for 2 hours, treated with LPS (Lipopolysaccharide, 100 ng / mL), and cultured for 18 hours. Subsequently, 100 μL of the supernatant obtained by centrifuging the culture medium was mixed with an equal volume of Griess reagent and reacted at room temperature for 10 minutes; afterward, the absorbance was measured at a wavelength of 540 nm using a microplate reader. NO production was expressed as a multiple relative to the control group treated with the vehicle. Dexamethasone (Dex, 5 μM) was used as a positive control.

[0071] As a result, as shown in Figure 2, NO production was significantly increased in the control group (LPS-only treatment group) compared to the normal group (sample and LPS-untreated group), and NO production was significantly decreased in the sample-treated group compared to the control group. In particular, among the sample-treated groups, NO production was lower in the SRT and Met combined treatment group compared to the SRT-only treatment group (based on the same SRT treatment concentration). From the above results, it was confirmed that SRT and Met combined treatment inhibits NO production.

[0073] [Example 3] Analysis of pro-inflammatory cytokines

[0074] To determine the effect of the sample on the secretion of pro-inflammatory cytokines, an ELISA analysis was performed to measure the secretion amounts of IL-1β and IL-6. 100 μL of the supernatant used in Example 2 above was Cymax TM Experiments were performed using the Mouse IL-1β ELISA Kit (AbFrontier, Seoul, Korea) and Mouse IL-6 ELISA Kit (Elabscience) according to the provided protocols, and absorbance was measured at a wavelength of 450 nm using a microplate reader. Dexamethasone (Dex, 5 μM) was used as a positive control.

[0075] As a result, as shown in Figure 3, the secretion of IL-1β and IL-6 was significantly increased in the control group (LPS alone treatment group) compared to the normal group (sample and LPS untreated group), and the secretion of IL-1β and IL-6 was significantly decreased in the sample treatment group compared to the control group. In particular, among the sample treatment groups, the secretion of IL-1β and IL-6 was lower in the SRT and Met combination treatment group compared to the SRT alone treatment group (based on the same SRT treatment concentration). From the above results, it was confirmed that SRT and Met combination treatment inhibits the secretion of IL-1β and IL-6.

[0077] [Example 4] Analysis of inflammation-related factor expression

[0078] To determine the effect of the samples on the expression of inflammation-related factors, Western blots were performed to measure the expression of iNOS (Inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2). RAW 264.7 cells cultured in serum-free medium for at least 6 hours were pretreated with SRT (100 μg / ml) or / and Met (1 mM) for 2 hours, treated with LPS 100 ng / mL, and cultured for 18 hours. For protein extraction, the cells were washed twice with PBS, lysed with RIPA buffer (Thermo Fisher Scientific, Rockford, IL, USA), and centrifuged at 12,000 × g for 30 minutes to collect the supernatant. Protein concentrations were measured using a Bicinchoninic acid protein assay kit (Thermo Fisher Scientific), and protein samples were prepared using sample buffer (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), and the protein was transferred to a PVDF membrane. To block non-specific binding of antibodies to the membrane, the membrane was treated with a blocking buffer (5% non-fat milk) for 1 hour and washed with a PBST (Phosphate-Buffered Saline with Tween 20) solution containing 0.1% Tween 20.After that, protein antibodies (COX-2, iNOS, and β-actin) were used for treatment overnight at 4°C, and HRP-linked anti-rabbit or anti-mouse was used as the secondary antibody. After reacting with an enhanced chemiluminoescence solution (Amersham, Piscataway, NJ, USA), the expression levels of each protein were observed and images were acquired using a Fusion Solo-2 image analyzer (Vilber Lourmat, Paris, France).

[0079] As a result, as shown in Figure 4, iNOS and COX-2 expression was significantly increased in the control group (LPS alone treatment group) compared to the normal group (sample and LPS untreated group), and iNOS and COX-2 expression was significantly decreased in the sample treatment group compared to the control group. In particular, among the sample treatment groups, iNOS and COX-2 expression was lower in the SRT and Met combination treatment group compared to the SRT alone treatment group (based on the same SRT treatment concentration). From the above results, it was confirmed that SRT and Met combination treatment reduces iNOS and COX-2 expression.

[0081] [Example 5] Estradiol Analysis

[0082] To determine the effect of the sample on steroid hormone production in granulosa cells, ELISA analysis was performed to measure estradiol secretion. COV434 cells cultured in serum-free medium for more than 24 hours were pretreated with SRT (10, 100, or 300 μg / ml) or / and Met (1 mM) for 2 hours, and then treated with FSH (follicle stimulating hormone, 30 ng / mL) and AD (androstenedione, 10 μM) to induce estradiol secretion, followed by 24 hours of culture. Subsequently, 100 μL of the supernatant obtained by centrifuging the culture medium was applied to the E2 (Estradiol) ELISA Kit (Elabscience) and measured according to the provided protocol.

[0083] As a result, as shown in Figure 5, the amount of estradiol secreted was significantly increased in the control group (FSH and AD treated group) compared to the normal group (sample, FSH and AD untreated group), and the amount of estradiol secreted was significantly decreased in the sample treated group compared to the control group. In particular, among the sample treated groups, the amount of estradiol secreted was lower in the SRT and Met combined treated group compared to the SRT alone treated group (based on the same SRT treatment concentration). From the above results, it was confirmed that the combined treatment of SRT and Met inhibits estradiol secretion.

[0085] [Example 6] Analysis of the effect of improving polycystic ovary syndrome

[0086] Animal experiments were conducted to determine the effects of the samples on polycystic ovary syndrome (hereinafter referred to as PCOS). The experimental groups were set as follows. All animal experiments were performed in accordance with the guidelines approved by the Animal Ethics Committee of Dongguk University (Approval No.: 2023-03248).

[0087] 1) Control group: Normal rats + tap water

[0088] 2) Control group: PCOS rats + tap water

[0089] 3) Sample Treatment Group 1 (SRT Alone Treatment Group): PCOS rats + SRT (1000 mg / kg)

[0090] 4) Sample Treatment Group 2 (Met alone treatment group): PCOS rats + Met (100 mg / kg)

[0091] 5) Sample Treatment Group 3 (SRT and Met combination treatment group): PCOS rats + SRT (1000 mg / kg) + Met (100 mg / kg)

[0092] PCOS was induced in the control group and sample treatment group by dissolving 4 mg of estradiol valerate (Sigma-Aldrich, USA) in 0.2 ml of sesame oil (Sigma-Aldrich, USA) and administering it once via intramuscular injection. The normal group received a single intramuscular injection of 0.2 ml of regular sesame oil. Starting 6 weeks after the injection of the estradiol valerate, the sample treatment group was orally administered SRT (total dose: 1000 mg / kg) or / and Met (total dose: 100 mg / kg) five times a week for 5 weeks (SRT and Met were dissolved in tap water and administered to the animal model). The normal group and control group received tap water instead of the sample five times a week for 5 weeks via oral injection. Subsequently, changes in follicles following sample treatment were analyzed.

[0093] For histopathological analysis, the above animal model was sacrificed, one ovary and uterus were excised, fixed in 10% formalin, paraffin-embedded, and 5 μm sections were prepared and stained with Hematoxylin-Eoxin (H&E). The slides were scanned using a whole slide scanner (3DHISTECH Ltd, Budapest, Hungary) and CaseViewer TM Images were acquired and analyzed using software (3DHISTECH Ltd).

[0094] For serum analysis, blood was obtained from the animal model by cardiac blood sampling on the last day of the experiment and centrifuged at 3000 rpm for 15 minutes using a centrifuge (Beckman Coulter, Fullerton, CA) to collect the supernatant. To measure the concentrations of testosterone, estradiol, FSH (follicle-stimulating hormone), and LH (luteinizing hormone) in the obtained serum, an ELISA kit was purchased from Elabscience (USA). To measure the concentrations of AST (aspartate aminotransferase) and ALT (alanine aminotransferase), which are indicators of liver damage, AsanSET GOT (glutamic oxaloacetic transaminase) and GPT (glutamic pyruvic transaminase) reagents (Asan Pharmaceutical Co., Ltd., Seoul, Korea) were purchased and measured according to the manufacturer's manual.

[0095] As a result, as shown in Figure 6, compared to the normal group (Normal), the number of cystic follicles (Cyst No.) in the ovaries significantly increased and the number of graafian follicles (GF No.) significantly decreased in the control group (PCOS), whereas compared to the control group, the number of cystic follicles in the ovaries significantly decreased and the number of graafian follicles significantly increased in the sample-treated group. In particular, the decrease in the number of cystic follicles and the increase in the number of graafian follicles in the ovaries were more significant in the sample combination treatment group (M+S) compared to the sample-alone treatment group (M and S).

[0096] In addition, as shown in Figure 7, blood testosterone, estradiol, and LH concentrations significantly increased and blood FSH concentrations significantly decreased in the control group compared to the normal group (Con), whereas blood testosterone, estradiol, and LH concentrations significantly decreased and blood FSH concentrations increased in the sample-treated group compared to the control group. In particular, the decrease in blood testosterone, estradiol, and LH concentrations and the increase in blood FSH concentrations were more significant in the sample combination treatment group (M+S) compared to the sample-alone treatment group (M and S).

[0097] In addition, as shown in Figure 8, there were no significant differences in blood AST and ALT concentrations among all experimental groups.

[0098] From the above results, it was confirmed that combined treatment with SRT and Met improved PCOS without exhibiting hepatotoxicity.

[0100] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. That is, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome or related diseases comprising Siryung-Tang and metformin as active ingredients, wherein the diseases related to polycystic ovary syndrome are one or more selected from the group consisting of hyperandrogenism, amenorrhea, hypomenorrhea, dysfunctional uterine bleeding, premature menopause, infertility, and endometriosis. Claim 2 In paragraph 1, the above Silyeongtang is Bupleurum ( Bupleurum falcatum Linne), Taxa ( Alisma orientale Juzepzuk), Atractylodes ( Atractylodes macrocephala Koidzumi), low spirit ( Polyporus umbellatus Fries), Poria cocos ( Poria cocos Wolf), Banha ( Pinellia ternata Breitenbach), gold ( Scutellaria baicalensis Georgi), ginseng ( Panax ginseng CA Meyer), licorice ( Glycyrrhiza uralensis Fischer), broiler chicken ( Cinnamomum cassia J.Presl) and ginger ( Zingiber officinale A pharmaceutical composition characterized by including Roscoe. Claim 3 delete Claim 4 A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition inhibits the generation of nitric oxide. Claim 5 A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition inhibits the expression of one or more selected from the group consisting of IL-1β (Interleukin-1β), IL-6 (Interleukin-6), iNOS (Inducible nitric oxide synthase), COX-2 (cyclooxygenase-2), and estradiol. Claim 6 A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition reduces the concentration of testosterone, estradiol, or luteinizing hormone in the blood, or increases the concentration of follicle-stimulating hormone in the blood. Claim 7 A health functional food composition for preventing or improving polycystic ovary syndrome or related diseases, comprising Siryung-Tang and metformin as active ingredients, wherein the diseases related to polycystic ovary syndrome are one or more selected from the group consisting of hyperandrogenism, amenorrhea, hypomenorrhea, dysfunctional uterine bleeding, premature menopause, infertility, and endometriosis. Claim 8 delete Claim 9 delete Claim 10 delete